Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Rhinitis

In brief

The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Key facts

Study ID

NCT00406094

Run by

Bernstein, Jonathan A., M.D.

People needed

6

Starts

2006-11-01

Expected to finish

2009-12-01

Last updated by the study team

2009-01-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 - 65 years
• Diagnosed with NARES

You may not qualify if…

• Smokers, exposed to passive smoke
• Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)

Where it is running

• Bernstein Allergy Group — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.